Eric Dein, MD, shared rheumatology perspectives with five congressional offices on Sept. 28 as part of the virtual Hill Day. Read his hour-by-hour account, including staffer education, legislative requests and prior authorization woes.
Search results for: health insurance
Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis
Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to…
Minnesota Joins Dakotas to Form Growing Rheumatology Association
A relatively new state association, the Rheumatology Association of Minnesota and the Dakotas (RA-MD), held its first meeting in 2016. Five years later, the association president, Jody Hargrove, MD, a board-certified rheumatologist with Arthritis and Rheumatology Consultants PA, Edina, Minn., says the group’s membership fluctuates between 80 and 100 rheumatology professionals. RA-MD has members from…
Case Report: A 5-Year-Old with an Ischemic Digit
Janus kinase 1 and 2 inhibitors (jakinibs) have been approved for the treatment of rheumatoid arthritis, psoriatic arthritis and, most recently, juvenile idiopathic arthritis. They have also shown promise in the treatment of interferon (IFN) mediated diseases. The Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway is the principal signaling pathway for…
ACR Practice Experts Can Answer Challenging Business Questions
Coding questions and billing compliance are just a few of the issues ACR practice management specialists can help managers and rheumatologists navigate to recoup reimbursement and ensure timely patient treatment.
FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…
Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions
As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.
3 Educators Offer Lessons Learned on Rheumatology Training
Leslie Kahl, MD, on Coaching I have been an academic clinician-educator for my entire career and, like most of my colleagues, have been called upon to advise, mentor and coach countless trainees and junior faculty members. Unlike most clinician-educators, though, I also served as associate dean for student affairs at Washington University School of Medicine,…
High Cost of Specialty Drugs Demands Action
Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.
A Unified Advocacy Voice for Rheumatology
One thing that became clear very quickly this past year was that the COVID-19 pandemic would change the way we deliver care to patients. What has not changed amid an evolving healthcare landscape is our driving focus to ensure our patients’ access to rheumatology care and the availability of state-of-the-art treatments. We know you share…
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 116
- Next Page »